The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
5168
The Oral Apelin Receptor Agonist Azelaprag Enhances Glycemic Control in Preclinical Models of Diabetic Obesity Both as Monotherapy and in Combination with Tirzepatide
Date
June 21, 2025
Explore related products in the following collection: